High-intensity care for GDMT titration
J Biegus, M Pagnesi, B Davison, P Ponikowski… - Heart Failure …, 2024 - Springer
Heart failure (HF) is a systemic disease associated with a high risk of morbidity, mortality,
increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic …
increased risk of hospitalizations, and low quality of life. Therefore, effective, systemic …
Guidelines for Treating Heart Failure
MM Kittleson - Trends in Cardiovascular Medicine, 2024 - Elsevier
Optimal guideline-directed medical therapy for heart failure with reduced ejection fraction
comprises the angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan), an evidence …
comprises the angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan), an evidence …
Use of Potentially Nephrotoxic Drugs in Type 2 Diabetes Patients on SGLT2i: A Trajectories Analysis
Purpose To characterize trajectories of nephrotoxic potential (NxP) drug use among older
adults with Type 2 Diabetes (T2D) treated with SGLT2is and identify associated patient …
adults with Type 2 Diabetes (T2D) treated with SGLT2is and identify associated patient …
[HTML][HTML] Health Equity Across the Life Course: A Call to Action for the Cardiovascular Community
S Al-Kindi, AL Bailey, P Douglass - JACC: Advances, 2024 - jacc.org
The field of cardiovascular medicine has made tremendous scientific advances in recent
decades, leading to improved health outcomes for many. However, these gains have not …
decades, leading to improved health outcomes for many. However, these gains have not …
[HTML][HTML] Lessons to Adhere to for Optimizing Heart Failure Medications
C Ploenzke, W Simons, O Vardeny - JACC: Advances, 2024 - jacc.org
Heart failure is an established global public health burden that affects 64 million people
worldwide. 1 Hospitalizations for heart failure cost w $24,000 each and account for 65% of …
worldwide. 1 Hospitalizations for heart failure cost w $24,000 each and account for 65% of …